Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gefitinib in EGFR amplification–refractory solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• Gefitinib (Gefitinib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Solid Tumor | Phase 2 | Status: COMPLETED